Chemotherapy-Induced Nausea and Vomiting (CINV) Based on Blood Types among Cancer Patients in Yogyakarta, Indonesia
Dublin Core
Title
Chemotherapy-Induced Nausea and Vomiting (CINV) Based on Blood Types among Cancer Patients in Yogyakarta, Indonesia
Subject
Blood group; cancer; CINV;
Yogyakarta
Yogyakarta
Description
Background: Studies related to blood type in cancer patients have been conducted
extensively, but they are inclined to cancer incidence or survival rate. Meanwhile,
there is limited research on Chemotherapy-Induced Nausea and Vomiting (CINV),
the most disturbing side effect of chemotherapy, in relation to blood type.
Purpose: This study aimed to compare CINV frequency in cancer patients by blood
groups in Yogyakarta, Indonesia.
Methods: A descriptive comparative study with a cross-sectional approach was
conducted purposively on 70 chemotherapy patients in two hospitals in Yogyakarta.
Patients with anticipatory CINV and brain cancer (primary or metastases) were
excluded. The data were collected between July and November 2020 using a sheet
for patient characteristics and a filled-in diary from the first to the seventh day post-
chemotherapy to collect CINV data. The descriptive statistics and Kruskal Wallis test
were used to analyze the data.
Results: Of 70 total samples, most of them were breast cancer (71.4%) and were in
stage IV (50%). They received chemotherapy alone as their primary therapy (94.3%)
and received moderate to high emetogenic agents (31.4% and 35.7%). Samples
mostly had A blood type (34.3%) and had undergone chemotherapy for 3-18 months
(min-max). As many as 64.6% of patients experienced CINV with a delayed type and
experienced moderate severity (52.9%). The bivariate test showed no difference in
CINV frequencies based on blood groups in general (p=0.068). However, based on
the CINV onset, there was a significant difference in CINV frequencies in the A blood
group against other blood groups (p=0.020) on the fourth post-chemotherapy day.
Conclusions: Unless the fourth-day post-chemotherapy, the frequency of CINV
based on blood groups showed no difference. Since CINV incidence is still high, the
provision of both pharmacological and non-pharmacological therapy to treat CINV
has to be given to patients after chemotherapy. Blood group factors can be considered
for more extensive management, especially in delayed CINV cases.
extensively, but they are inclined to cancer incidence or survival rate. Meanwhile,
there is limited research on Chemotherapy-Induced Nausea and Vomiting (CINV),
the most disturbing side effect of chemotherapy, in relation to blood type.
Purpose: This study aimed to compare CINV frequency in cancer patients by blood
groups in Yogyakarta, Indonesia.
Methods: A descriptive comparative study with a cross-sectional approach was
conducted purposively on 70 chemotherapy patients in two hospitals in Yogyakarta.
Patients with anticipatory CINV and brain cancer (primary or metastases) were
excluded. The data were collected between July and November 2020 using a sheet
for patient characteristics and a filled-in diary from the first to the seventh day post-
chemotherapy to collect CINV data. The descriptive statistics and Kruskal Wallis test
were used to analyze the data.
Results: Of 70 total samples, most of them were breast cancer (71.4%) and were in
stage IV (50%). They received chemotherapy alone as their primary therapy (94.3%)
and received moderate to high emetogenic agents (31.4% and 35.7%). Samples
mostly had A blood type (34.3%) and had undergone chemotherapy for 3-18 months
(min-max). As many as 64.6% of patients experienced CINV with a delayed type and
experienced moderate severity (52.9%). The bivariate test showed no difference in
CINV frequencies based on blood groups in general (p=0.068). However, based on
the CINV onset, there was a significant difference in CINV frequencies in the A blood
group against other blood groups (p=0.020) on the fourth post-chemotherapy day.
Conclusions: Unless the fourth-day post-chemotherapy, the frequency of CINV
based on blood groups showed no difference. Since CINV incidence is still high, the
provision of both pharmacological and non-pharmacological therapy to treat CINV
has to be given to patients after chemotherapy. Blood group factors can be considered
for more extensive management, especially in delayed CINV cases.
Creator
Dwi Kartika Rukmi1
, Muhamat Nofiyanto2
, Muhamat Nofiyanto2
Source
https://doi.org/10.14710/nmjn.v13i2.48272
Date
3 July 2023
Contributor
PERI IRAWAN
Format
PDF
Language
ENGLISH
Type
TEXT
Files
Collection
Citation
Dwi Kartika Rukmi1
, Muhamat Nofiyanto2, “Chemotherapy-Induced Nausea and Vomiting (CINV) Based on Blood Types among Cancer Patients in Yogyakarta, Indonesia,” Repository Horizon University Indonesia, accessed February 21, 2026, https://repository.horizon.ac.id/items/show/11192.